Wuxi PharmaTech Inc (NYSE: WX) has spent ¥100 million ($1 = ¥6.83) registering a pharmaceutical research and development facility in the Mashan Bio-Park of Wuxi, Jiangsu province. Covering 66,700 square meters in land area, it is expected to process $200 million annually worth of outsourced R&D and production in relation to antibiotics, vaccines and recombinant DNA proteins.
You are currently reading
total words in this article.
To continue reading this article, you must be a subscriber. Log in now..